ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.

Zacks Investment Research • Aug 14, 2026

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?

ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.

Zacks Investment Research • Aug 14, 2026

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported upbeat earnings for the second quarter on Friday.

Benzinga • Aug 10, 2026

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.

Zacks Investment Research • Aug 10, 2026

ANI Pharmaceuticals Q2 Earnings Call Highlights

ANI Pharmaceuticals NASDAQ: ANIP reported record second-quarter revenue and adjusted EBITDA as growth in its Cortrophin Gel rare-disease franchise and generics business lifted results, while the company modestly reduced its full-year Cortrophin revenue outlook to reflect first-half performance.

MarketBeat • Aug 7, 2026

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin ® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year Quarterly GAAP net income available to common shareholders of $24.7 million; Quarterly adjusted non-GAAP EBITDA of $71.6 million, an increase of 32.4% year-over-year Diluted GAAP income per share of $1.05 and adjusted non-GAAP diluted earnings per share of $2.21 Reaffirming 2026 guidance for total net revenue of $1,080 - $1,140 million and adjusted non-GAAP EBITDA of $285 - $300 million PRINCETON, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2026.

GlobeNewsWire • Aug 7, 2026

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $1.8 per share a year ago.

Zacks Investment Research • Aug 7, 2026

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Aug 7, 2026

ANI Pharmaceuticals: The Market Is Pricing The Present, Not The Future

ANI Pharmaceuticals is rated Buy at ~$80, with a 12-month fair value set at $95, as the current valuation undervalues 2027 earnings potential. 2026 results are depressed by upfront gout expansion costs and higher Corticotrophin royalties, but revenue and operating leverage from these investments are expected to materialize in 2027. Most 2026 Cortrophin growth is projected from established indications, not the new gout initiative, which is viewed as a 2027 upside driver.

Seeking Alpha • Aug 6, 2026